Home > Focus Areas > DLBCL Connect > Post
  • Saved

4yr

Paper: Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma

Paper: Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma

Source : https://ash.confex.com/ash/2020/webprogram/Paper140965.html?utm_source=miragenews&utm_medium=miragenews&utm_campaign=news

Oral and Poster Abstracts Oral 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Retrospective/Observational Studies: Biomarkers and Prognostication in Aggressive B-Cell Non-Hodgkin Lymphomas Adult, Diseases, Therapies, DLBCL, B-Cell Lymphoma, Technology and Procedures, Lymphoid Malignancies, Study Population, Clinically relevant, molecular testing Reid W Merryman, MD 1, Robert A.

  • 4yr
    This important article advances the knowledge of circulating tDna in DLBCL and like many other articles, suggests the prognostic value of this assessment. I’m not aware of a commercially available assay presently but the sense is that this will eventually with furthe data be utilized in a clinical setting for prognostic and possibly predictive use.

You might also like